UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2025

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01 ~~Other~~Entry ~~Events.~~into a Material Definitive Agreement

On ~~August~~September 295, 2025, Emergent BioSolutions Inc. (the “~~Emergent~~Company,”) ~~received~~including aits ~~contract~~wholly-owned ~~modification~~subsidiaries, (“~~Modification No. 20~~Emergent”), ofthrough ~~the~~its ~~BARDA~~wholly-owned ~~AV7909~~subsidiary, ~~Contract~~Emergent ~~(as~~Product ~~defined~~Development ~~below)~~Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response to(“ASPR”), ~~procure~~an ~~additional~~agency ~~doses~~ of ~~CYFENDUS™~~the ~~(Anthrax~~U.S. ~~Vaccine~~Department ~~Adsorbed,~~of ~~Adjuvanted)~~Health ~~(previously~~and ~~known~~Human asServices (“~~AV7909~~Modification No. 14”), ~~valued~~exercising atOption ~~$30.0~~Year ~~million.~~6 ~~This~~for ~~modification~~Emergent ~~relates~~ to ~~Emergent’s~~supply ~~AV7909~~ACAM2000® ~~development~~(Smallpox ~~and~~(Vaccinia) ~~procurement~~Vaccine, ~~contract~~Live) ~~with~~to the ~~Biomedical~~U.S. ~~Advanced~~government ~~Research~~under ~~and~~Emergent’s ~~Development~~existing ~~Authority~~10-year contract with ASPR (the “~~BARDA~~ACAM2000 Contract”),. ~~which~~Modification ~~became~~No. ~~effective~~14 onis ~~September~~valued ~~30,~~at ~~2016~~$56 ~~(the~~million ~~“BARDA~~and ~~AV7909~~requires ~~Contract”)~~Emergent ~~and~~to ~~has~~deliver ~~been~~doses ~~modified~~of ~~from~~ACAM2000 ~~time~~ to ~~time~~the U.S. government by December 31, 2025.

The preceding description of Modification ~~No.~~14 20 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No14. ~~20.~~A ~~Modification~~copy ~~No.~~of ~~20,~~Modification ~~with~~14 ~~relevant~~is ~~redactions~~expected to ~~protect~~be ~~confidential~~filed ~~and~~as ~~sensitive~~an ~~information,~~exhibit isto ~~filed~~the ~~herewith~~Company’s asnext ~~Exhibit~~Quarterly ~~10.1~~Report ~~and~~on isForm ~~incorporated herein by reference~~10-Q. The ~~BARDA~~ACAM2000 ~~AV7909~~ Contract is filed as a material agreement of Emergent as ~~Exhibit~~exhibit 10.5748 with ~~Emergent~~the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2024~~2019.

OnItem ~~September 2, 2025, Emergent issued a press release announcing the contract modification~~7.01 Regulation AFD ~~copy of the press release is furnished as Exhibit 99~~Disclosure.~~1 to this Current Report and incorporated herein by reference.~~

On September 9, 2025, the Company issued a press release announcing Modification No. 14. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
10.1						Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract.
99.1						Press release issued by Emergent BioSolutions Inc. on September 9, 2025.
99.1						Press release issued by Emergent BioSolutions Inc. on September 2, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EMERGENT BIOSOLUTIONS INC.
Dated: September 5, 2025	By:	/s/ RICHARD S. LINDAHL
Dated: September 11, 2025	By:	/s/ RICHARD S. LINDAHL
		Name: Richard S. LindahlTitle: Executive Vice President, Chief Financial Officer and Treasurer

Filing Compare · Emergent BioSolutions Inc.